Transporters and drug therapy: Implications for drug disposition and disease

被引:338
作者
Ho, RH
Kim, RB
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pediat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.clpt.2005.05.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response. Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process. However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play critical roles in the overall disposition of numerous drugs in clinical use. In addition to their roles in xenobiotic transport, drug transporters often mediate important physiologic functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are critical for maintenance of normal homeostasis. In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clinical implications of transporters to drug-drug interactions and subsequent development of adverse effects, inter-individual variability in drug response, and human disease.
引用
收藏
页码:260 / 277
页数:18
相关论文
共 148 条
  • [51] Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    Hoffmeyer, S
    Burk, O
    von Richter, O
    Arnold, HP
    Brockmöller, J
    Johne, A
    Cascorbi, I
    Gerloff, T
    Roots, I
    Eichelbaum, M
    Brinkmann, U
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3473 - 3478
  • [52] Illmer T, 2002, CANCER RES, V62, P4955
  • [53] Imai Y, 2002, MOL CANCER THER, V1, P611
  • [54] Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy
    Jacquemin, E
    Cresteil, D
    Manouvrier, S
    Boute, O
    Hadchouel, M
    [J]. LANCET, 1999, 353 (9148) : 210 - 211
  • [55] The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood
    Jacquemin, E
    de Vree, JML
    Cresteil, D
    Sokal, EM
    Sturm, E
    Dumont, M
    Scheffer, GL
    Paul, M
    Burdelski, M
    Bosma, PJ
    Bernard, O
    Hadchouel, M
    Elferink, RPJO
    [J]. GASTROENTEROLOGY, 2001, 120 (06) : 1448 - 1458
  • [56] Functional C3435T polymorphism of MDR1 gene:: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia
    Jamroziak, K
    Mlynarski, W
    Balcerczak, E
    Mistygacz, M
    Trelinska, J
    Mirowski, M
    Bodalski, J
    Robak, T
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (05) : 314 - 321
  • [57] EPIDEMIOLOGY OF DRUG-DRUG INTERACTIONS AS A CAUSE OF HOSPITAL ADMISSIONS
    JANKEL, CA
    FITTERMAN, LK
    [J]. DRUG SAFETY, 1993, 9 (01) : 51 - 59
  • [58] Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis
    Jansen, PLM
    Strautnieks, SS
    Jacquemin, E
    Hadchouel, M
    Sokal, EM
    Hooiveld, GJEJ
    Koning, JH
    De Jager-Krikken, A
    Kuipers, F
    Stellaard, F
    Bijleveld, CMA
    Gouw, A
    Van Goor, H
    Thompson, RJ
    Müller, M
    [J]. GASTROENTEROLOGY, 1999, 117 (06) : 1370 - 1379
  • [59] Jariyawat S, 1999, J PHARMACOL EXP THER, V290, P672
  • [60] Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner
    Kajinami, K
    Brousseau, ME
    Ordovas, JM
    Schaefer, EJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (08) : 1046 - 1050